Schedule 13D ownership disclosure

Arbutus Biopharma Corp

Common Shares, without par value · CUSIP: 03879J100

Event date: 2025-02-21

Filing-level shares
38,847,462
Percent of class
20.5%
  • Roivant Sciences Ltd.Reported CIK 0001635088

    Shares: 38,847,462 · Class: 20.5%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001140361-25-005770
Form type
SCHEDULE 13D/A
Filer
Arbutus Biopharma Corp
CIK
CIK 1447028
Filed
Feb 25, 2025
Reporting period
Feb 21, 2025
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub